Health Care Fund
Daily price w/o sales charge as of 03/27/2024
$19.67
$0.23
YTD Returns w/o sales charge as of 03/27/2024
8.55%
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basicsas of 02/29/2024
- Total Net Assets
- $8.49 M
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 3.10%
- Fund Net Expense Ratio
- 0.60%
- Number of Holdings
- 70
Fund Expense Ratio :
Gross 3.10%
Net 0.60%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 6.18% | 12.25% | 0.98% | - | - | 10.26% |
Lipper Category Avg. Health/Biotechnology Funds | 5.82% | 13.09% | 0.44% | - | - | - |
MSCI ACWI Health Care Index (Net) | 4.72% | 13.81% | 6.80% | - | - | 10.17% |
w/ sales charge | 6.18% | 12.25% | 0.98% | - | - | 10.26% |
Fund Expense Ratio :
Gross 3.10%
Net 0.60%
Fund Expense Ratio :
Gross 3.10%
Net 0.60%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 3.37% | 3.37% | -0.29% | - | - | 9.16% |
Lipper Category Avg. Health/Biotechnology Funds | 4.65% | 4.65% | -1.03% | - | - | - |
MSCI ACWI Health Care Index (Net) | 3.58% | 3.58% | 4.54% | - | - | 9.42% |
Fund Expense Ratio :
Gross 3.10%
Net 0.60%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM
Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 3.10%
Net 0.60%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 6.18% | 12.25% | 0.98% | - | - | 10.26% |
Lipper Category Avg. Health/Biotechnology Funds | 5.82% | 13.09% | 0.44% | - | - | - |
MSCI ACWI Health Care Index (Net) | 4.72% | 13.81% | 6.80% | - | - | 10.17% |
w/ sales charge | 6.18% | 12.25% | 0.98% | - | - | 10.26% |
Fund Expense Ratio :
Gross 3.10%
Net 0.60%
Fund Expense Ratio :
Gross 3.10%
Net 0.60%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 3.37% | 3.37% | -0.29% | - | - | 9.16% |
Lipper Category Avg. Health/Biotechnology Funds | 4.65% | 4.65% | -1.03% | - | - | - |
MSCI ACWI Health Care Index (Net) | 3.58% | 3.58% | 4.54% | - | - | 9.42% |
Fund Expense Ratio :
Gross 3.10%
Net 0.60%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
NAV Historical Prices
Date | Net Asset Value |
---|
Portfolio
Portfolio
Holding | Sector | Assets |
---|
Eli Lilly & Co | Health Care | 8.3% |
Novo Nordisk A/S | Health Care | 6.2% |
Intuitive Surgical Inc | Health Care | 3.5% |
Stryker Corp | Health Care | 2.7% |
AstraZeneca PLC | Health Care | 2.5% |
UnitedHealth Group Inc | Health Care | 2.3% |
Boston Scientific Corp | Health Care | 2.3% |
Krystal Biotech Inc | Health Care | 2.2% |
Natera Inc | Health Care | 2.2% |
Regeneron Pharmaceuticals Inc | Health Care | 2.2% |
Holding | Sector | Assets |
---|
Eli Lilly & Co | Consumer, Non-cyclical | 7.3% |
Novo Nordisk A/S | Consumer, Non-cyclical | 6.0% |
Intuitive Surgical Inc | Consumer, Non-cyclical | 3.6% |
AstraZeneca PLC | Consumer, Non-cyclical | 2.7% |
Stryker Corp | Consumer, Non-cyclical | 2.7% |
UnitedHealth Group Inc | Consumer, Non-cyclical | 2.5% |
Dexcom Inc | Consumer, Non-cyclical | 2.4% |
Boston Scientific Corp | Consumer, Non-cyclical | 2.2% |
Regeneron Pharmaceuticals Inc | Consumer, Non-cyclical | 2.2% |
Neurocrine Biosciences Inc | Consumer, Non-cyclical | 2.1% |
TransMedics Group Inc | Consumer, Non-cyclical | 2.1% |
Vertex Pharmaceuticals Inc | Consumer, Non-cyclical | 2.0% |
Blueprint Medicines Corp | Consumer, Non-cyclical | 1.8% |
Arcellx Inc | Consumer, Non-cyclical | 1.8% |
Glaukos Corp | Consumer, Non-cyclical | 1.8% |
Natera Inc | Consumer, Non-cyclical | 1.7% |
RxSight Inc | Consumer, Non-cyclical | 1.6% |
Krystal Biotech Inc | Consumer, Non-cyclical | 1.6% |
Cencora Inc | Consumer, Non-cyclical | 1.6% |
Danaher Corp | Consumer, Non-cyclical | 1.6% |
Siemens Healthineers AG | Consumer, Non-cyclical | 1.6% |
Cymabay Therapeutics Inc | Consumer, Non-cyclical | 1.5% |
Bridgebio Pharma Inc | Consumer, Non-cyclical | 1.5% |
iRhythm Technologies Inc | Consumer, Non-cyclical | 1.5% |
Stevanato Group SpA | Consumer, Non-cyclical | 1.4% |
Daiichi Sankyo Co Ltd | Consumer, Non-cyclical | 1.3% |
CVRx Inc | Consumer, Non-cyclical | 1.3% |
Xenon Pharmaceuticals Inc | Consumer, Non-cyclical | 1.3% |
Eisai Co Ltd | Consumer, Non-cyclical | 1.3% |
Shockwave Medical Inc | Consumer, Non-cyclical | 1.3% |
IDEXX Laboratories Inc | Consumer, Non-cyclical | 1.2% |
Cooper Cos Inc/The | Consumer, Non-cyclical | 1.2% |
Quanterix Corp | Consumer, Non-cyclical | 1.2% |
Sartorius Stedim Biotech | Consumer, Non-cyclical | 1.2% |
Merck & Co Inc | Consumer, Non-cyclical | 1.1% |
Insulet Corp | Consumer, Non-cyclical | 1.1% |
SpringWorks Therapeutics Inc | Consumer, Non-cyclical | 1.1% |
Crinetics Pharmaceuticals Inc | Consumer, Non-cyclical | 1.1% |
Argenx SE | Consumer, Non-cyclical | 1.0% |
West Pharmaceutical Services Inc | Consumer, Non-cyclical | 1.0% |
Rhythm Pharmaceuticals Inc | Consumer, Non-cyclical | 1.0% |
Gerresheimer AG | Industrial | 0.9% |
MoonLake Immunotherapeutics | Consumer, Non-cyclical | 0.9% |
Inspire Medical Systems Inc | Consumer, Non-cyclical | 0.9% |
Longboard Pharmaceuticals Inc | Consumer, Non-cyclical | 0.9% |
Nuvalent Inc | Consumer, Non-cyclical | 0.9% |
PROCEPT BioRobotics Corp | Consumer, Non-cyclical | 0.9% |
Schott Pharma AG & Co KGaA | Consumer, Non-cyclical | 0.9% |
Intra-Cellular Therapies Inc | Consumer, Non-cyclical | 0.8% |
Exact Sciences Corp | Consumer, Non-cyclical | 0.8% |
Thermo Fisher Scientific Inc | Consumer, Non-cyclical | 0.8% |
Disc Medicine Inc | Consumer, Non-cyclical | 0.8% |
Vaxcyte Inc | Consumer, Non-cyclical | 0.8% |
Penumbra Inc | Consumer, Non-cyclical | 0.8% |
Swedish Orphan Biovitrum AB | Consumer, Non-cyclical | 0.8% |
Pulmonx Corp | Consumer, Non-cyclical | 0.7% |
ConvaTec Group PLC | Consumer, Non-cyclical | 0.7% |
Apellis Pharmaceuticals Inc | Consumer, Non-cyclical | 0.7% |
Veracyte Inc | Consumer, Non-cyclical | 0.7% |
Ascendis Pharma A/S | Consumer, Non-cyclical | 0.7% |
Immunovant Inc | Consumer, Non-cyclical | 0.7% |
Bio-Techne Corp | Consumer, Non-cyclical | 0.7% |
Laboratory Corp of America Holdings | Consumer, Non-cyclical | 0.7% |
Fusion Pharmaceuticals Inc | Consumer, Non-cyclical | 0.7% |
Vera Therapeutics Inc | Consumer, Non-cyclical | 0.6% |
10X Genomics Inc | Consumer, Non-cyclical | 0.5% |
Molina Healthcare Inc | Consumer, Non-cyclical | 0.5% |
Madrigal Pharmaceuticals Inc | Consumer, Non-cyclical | 0.5% |
Evolus Inc | Consumer, Non-cyclical | 0.2% |
Fees & Expenses
Fees & Expenses
Expense Ratioas of 02/29/2024
Fund Gross Expense Ratio | Fund Net Expense Ratio | |
---|---|---|
3.10% | 0.60% |
Expense ratio details, Click here.
The net expense ratio takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2025. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.
Fund Documents
Fund Documents
0Documents selected
|
||||
---|---|---|---|---|
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
Summary Prospectus
Publish Date:11/03/2015
|
||||
Statutory Prospectus
Publish Date:11/03/2015
|
||||
SAI
Publish Date:11/03/2015
|
||||
Annual Report
Publish Date:11/03/2015
|
||||
Semi-Annual Report
Publish Date:11/03/2015
|
||||
Fact Sheet
Publish Date:11/03/2015
|